NCT00390884已完成4 期
Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 173
- 试验地点
- 5
- 主要终点
- Percentage of Seroprotected Participants Post-vaccination With Fluzone®
研究概览
简要总结
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 11 Months 至 14 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Previously enrolled in study GRC28 and received 2 vaccinations of the assigned lot.
- •Considered to be in good health on the basis of reported medical history and history-directed physical evaluation.
- •Available for the duration of the study.
- •Parent/legal representative willing and able to provide informed consent.
- •Parent/legal representative able to attend all scheduled visits and comply with all trial procedures.
- •Parent/legal representative willing to permit venipuncture for purposes of collecting a blood sample.
排除标准
- •Receipt of any vaccine within the past 7 days (subjects may be deferred until after the seven days has passed.)
- •Reported allergy to egg proteins, chicken proteins or any other constituent of the vaccine.
- •Ever received any influenza vaccine, other than at Visits 1 and 2 of study GRC28, or known to have ever been diagnosed with laboratory-confirmed influenza.
- •An acute illness with fever (rectal temperature ≥ 100.4°F [38.0°C]) in the 72 hours preceding enrollment in the trial (defer enrollment).
- •Known bleeding disorder.
- •Participation in any other interventional clinical trial within 30 days prior to enrollment, or planned participation in another interventional clinical trial prior to termination of the subject's participation in the study.
- •Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth.
- •Personal or immediate family history of congenital immune deficiency.
- •Developmental delay, neurologic disorder, or seizure disorder.
- •Chronic medical, congenital, or developmental disorder that, in the opinion of the investigator, could interfere with trial conduct or completion.
- •Known Human Immunodeficiency Virus (HIV)-positive mother or Hepatitis B surface antigen (HBsAg)-positive mother.
- •Known HIV, Hepatitis B, or Hepatitis C infection.
- •Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
- •Prior personal history of Guillain-Barré syndrome.
- •Any condition that, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.
研究组 & 干预措施
Fluzone®-Primed Group
Experimental
Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
干预措施: Influenza Virus Vaccine, Fluzone® (Biological)
Fluzone®-Naive Group
Experimental
Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
干预措施: Influenza Virus Vaccine, Fluzone® (Biological)
结局指标
主要结局
Percentage of Seroprotected Participants Post-vaccination With Fluzone®
时间窗: Day 28 Post-vaccination
Seroprotection was defined as a Post-vaccination Hemagglutination Inhibition titer of greater than or equal to 1:40.
次要结局
- Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibodies Post-vaccination With Fluzone®(Day 28 Post-vaccination)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of AgeInactivated Influenza VaccineNCT00242424Seattle Children's Hospital1,375
已完成
3 期
Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of AgeInfluenzaNCT00885105Sanofi Pasteur, a Sanofi Company242
已完成
4 期
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)InfluenzaNCT03546192Sanofi Pasteur, a Sanofi Company120
已完成
4 期
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in AdultsInfluenzaNCT01946438Sanofi Pasteur, a Sanofi Company208
已完成
4 期
Improving Immunogenicity of Influenza Vaccine in HIV Infected IndividualsHIV InfectionNCT01262846University of Pennsylvania195